louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02059018: The Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia
Official title: The Underlying Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Retinal Hypoxia
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2014-02-11
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The primary objective is to study if a stimulation of nitric oxide and/or prostaglandin affect the diameter changes of retinal vessels during hypoxia. Diameter changes are studied using the Dynamic Vessel Analyzer.


Eligibility criteria: Inclusion Criteria:

* Age between \>19 and \<61 years
* No known systemic or ocular diseases

Exclusion Criteria:

* Cardio-vascular disease
* Lung disease
* Epilepsy
* Previous ocular disease
* Previous treatment with medications influencing the intraocular pressure or the metabolism of nitric oxide or prostaglandins
* Daily intake of medicine except contraceptive pills
* Pregnancy or breastfeeding
* Known allergy against any of the drugs used in the interventions

Primary outcomes:
measure: Diameter changes of retinal vessels
timeFrame: Examination day 1 and 2
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Department of Ophtalmology, Aarhus University Hospital
Study officials:
affiliation: Aarhus University Hospital
name: Line Pedersen, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Aarhus University Hospital
name: Musa Kaya, stud.med
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00833118: Tongue Pull Versus Jaw Thrust
Official title: Tongue Pull Versus Jaw Thrust
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Surgery
Keywords: Surgery
General Anesthesia
Intubation
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2009-01-30
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Male or female scheduled for surgery and undergoing intubation for general anesthesia administration

Brief summary: This protocol seeks to determine the efficacy and reliability of a simple maneuver, the jaw thrust maneuver, in addition to cricoid pressure, in improving visualization of airway anatomy during video laryngoscopy. Hypothesis: The grade of view of the glottis as determined by the modified Cormack and Lehane grading system in anesthetized patients will improve by performing a jaw thrust maneuver during video laryngoscopy with compared with video laryngoscopy alone. Similarly, the grade of the view during cricoid pressure will also improve with a jaw thrust maneuver.


Eligibility criteria: Inclusion Criteria:

1. Age \> 18
2. Undergoing surgery and general anesthesia with endotracheal intubation
3. Able to give informed consent

Exclusion Criteria:

1. Trauma patients or emergent cases.
2. Patients who are unable to understand the proposed study
3. Patients who refuse participation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Sorin Brull, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05990218: Artificial Intelligence in the Detection of Right Sided Colonic Polyp in Different Operator Experience
Official title: Efficacy of Artificial Intelligence in the Detection of Right Sided Colonic Polyp in Operators with Different Endoscopic Experience: a Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Colon Polyp
Keywords: colon polyp
artificial intellegence
colonoscopy
Lead sponsor: Department of Medical Services Ministry of Public Health of Thailand
Sponsor class: OTHER_GOV
First posted: 2023-08-14
Enrollment: 240
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients randomized to 4 arms: control with experienced operator, control with beginner operator, AI with experienced operator, AI with beginner operator
Primary purpose: SCREENING

Brief summary: Colonoscopy is the gold standard modality for the detection of colonic polyp. However, miss polyp occurs especially in right sided colon. Artificial intelligence (AI) is one of the modality to improve polyp detection but the benefit of AI in operators with different endoscopic experience is still limited. This study aimed to evaluate the efficacy of AI in the detection of right sided colonic polyp in operators with different endoscopic experience by using double insertion of right side colon, back-to-back basis.


Eligibility criteria: Inclusion Criteria:

* participants age 40-80 years

Exclusion Criteria:

* History of colonic surgery (except appendectomy)
* Lower gastrointestinal bleeding
* unstable vital sign during endoscopy of pregnancy
* history of inflammatory bowel disease, polyposis syndrome, colon cancer, colonic stricture, abnormal coaglulation, organ failure

Primary outcomes:
measure: polyp detection rate
timeFrame: during endoscopy
Secondary outcomes:
measure: type of polyp
timeFrame: during endoscopy
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Rajavithi Hospital
Study officials:
References:
citation: Kamba S, Tamai N, Saitoh I, Matsui H, Horiuchi H, Kobayashi M, Sakamoto T, Ego M, Fukuda A, Tonouchi A, Shimahara Y, Nishikawa M, Nishino H, Saito Y, Sumiyama K. Reducing adenoma miss rate of colonoscopy assisted by artificial intelligence: a multicenter randomized controlled trial. J Gastroenterol. 2021 Aug;56(8):746-757. doi: 10.1007/s00535-021-01808-w. Epub 2021 Jul 3.
Clinical trial NCT00777218: Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine
Official title: Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Migraine
Keywords: migraine
Lead sponsor: University of South Alabama
Sponsor class: OTHER
First posted: 2008-10-22
Enrollment: 0
Sex: ALL
Minimum age (years): 8
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to determine if there are significant differences in the side effects related to memory, repetition and recall among these three drugs when used in a pediatric population.


Eligibility criteria: Inclusion Criteria:

* diagnosis of migraine with and without aura or chronic daily headache as defined by IHS
* subjects must between the age of 8-17 (inclusive)

Exclusion Criteria:

* diagnosis of tension-type headache or cluster headache

Primary outcomes:
measure: Record if memory, repetition or recall was impaired by subject during specific time frame on medication.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Mobile
country: United States
facility: University of South Alabama Department of Neurology
state: Alabama
Study officials:
affiliation: University of South Alabama Department of Neurology
name: J. I. Lopez, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06078618: Place of Birth and Neonatal Health in Cases of Premature Birth Between 32 and 36 Weeks of Amenorrhoea
Official title: Place of Birth and Neonatal Health in Cases of Preterm Birth Between 32 and 36 Weeks of Amenorrhoea: a National Population-based Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Premature Between 32 and 36 Weeks of Amenorrhoea
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2023-10-12
Enrollment: 240000
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Retrospective cohort based on an extraction from the National Health Data System (SNDS) and including all pregnant women giving birth between 32 and 36 completed weeks of amenorrhoea, between 1st January 2015 and 31st December 2020 in France and their newborn babies (live or stillborn).

Brief summary: Moderate and late premature babies (32-36 weeks of amenorrhoea) account for around 6% of births, but 20% of neonatal deaths. These children also have an increased risk of neonatal morbidity and long-term neurodevelopmental sequelae compared with full-term newborns.

In the case of preterm birth, optimal antenatal, birth and postnatal management is necessary to prevent neonatal complications and mitigate longer-term consequences. However, we lack knowledge about the management of this at-risk population and the factors influencing their health.

This knowledge is needed in the current context of unfavourable trends in neonatal health. Over the last ten years, neonatal and infant mortality has stagnated in France, with France falling behind other European countries. According to the latest European report, France ranks 22nd out of 33 countries. The causes of this stagnation are not well known, but many hypotheses have been put forward, including sub-optimal organisation of care.


Eligibility criteria: Inclusion Criteria:

* All mothers and their newborn babies (live or stillborn) who had a delivery stay between 32 and 36 days of age recorded in the PMSI between 01/01/2015 and 31/12/2020.

Exclusion Criteria:

* Births in very small maternity units
* Births in hospitals without an obstetrics unit
* Births outside hospitals.

Primary outcomes:
measure: Mortality rate
timeFrame: up to 28 days after birth
measure: Neonatal morbidity rate
timeFrame: up to 28 days after birth
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: Chu Dijon Bourgogne
Study officials:
References:
Clinical trial NCT02939118: One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™
Official title: A One-Year, Multicenter, Observational, Follow-up Safety Study in Subjects Previously Implanted With VC-01™ Combination Product
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Type 1 Diabetes Mellitus
Lead sponsor: ViaCyte
Sponsor class: INDUSTRY
First posted: 2016-10-19
Enrollment: 51
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All subjects who have been exposed to implanted VC-01™ in any ViaCyte clinical trial.

Brief summary: The purpose of this trial is to evaluate the long-term safety in subjects previously implanted with VC-01™ combination product.


Eligibility criteria: Inclusion Criteria:

* Previous implantation of VC-01™ combination product with subsequent explantation of all VC-01 units.

Exclusion Criteria:

* There are no exclusion criteria for this trial.

Primary outcomes:
measure: Incidence of adverse events reported during the study.
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03344718: Metabolic Syndrome and Vitamin D Level in Old People
Official title: Inverse Relationship Between Metabolic Syndrome and Vitamin D Level in Old People Without Vitamin D Deficiency
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Elderly
Metabolic Syndrome
Vitamin D Deficiency
Ostreocalcin
Insulin Resistance
Obesity
Osteoporosis
Sarcopenia
Lead sponsor: National Cheng-Kung University Hospital
Sponsor class: OTHER
First posted: 2017-11-17
Enrollment: 549
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Tianliao District, located in Kaohsiung City in southern Taiwan, is a tropical, agriculture-based community. It is located at around 22N50' latitude, like Hawaii (18° 55' N to 28° 27' N), and about 7° farther south than Florida (24° 27' N to 31° 00' N). The annual average temperature is 25.1°C (range: 19.3-29.2°C), and its annual average sunshine duration is 212.2 hours (longest: 221.4 hours in July; shortest: 161.8 hours in December). In the 2012 census report, the total population of Tianliao District was 7800, and 1966 (25.2%) participants were ≥ 65 years old.

Brief summary: In 2012, a cross-sectional survey sampling 1,966 community-dwelling old people was conducted. Structurized questionnaires were interviewed face-to-face by well-trained staffs. An overnight fasting blood were obtained for biochemistry parameters.


Eligibility criteria: Inclusion Criteria:

* more than 65-year-old

Exclusion Criteria:

* excluding empty houses, death, non-ambulatory subjects (subjects with significant disabilities, such as handicapped cerebral vascular accident, cancerous cachexia, unstable chronic diseases or psychiatric disorders, severe arthritis or inflammatory disease), uncomfortable anorexia by any medications, and non-reachable subjects

Primary outcomes:
measure: Osteoporotic fracture rate
timeFrame: 5 year
Secondary outcomes:
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: Department of Family Medicine, National Cheng Kung Univ Hosp
Study officials:
References:
citation: Wu CH, Chen KT, Hou MT, Chang YF, Chang CS, Liu PY, Wu SJ, Chiu CJ, Jou IM, Chen CY. Prevalence and associated factors of sarcopenia and severe sarcopenia in older Taiwanese living in rural community: the Tianliao Old People study 04. Geriatr Gerontol Int. 2014 Feb;14 Suppl 1:69-75. doi: 10.1111/ggi.12233.
Clinical trial NCT00120718: The Effect of Fasudil on Vascular Function in Humans
Official title: The Effect of Fasudil on Vascular Function in Humans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Atherosclerosis
Hypercholesterolemia
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
First posted: 2005-07-19
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate how the rho kinase inhibitor, fasudil, affects vascular function in patients with atherosclerosis and hyperlipidemia.


Eligibility criteria: Inclusion Criteria:

* Coronary artery disease
* Hyperlipidemia -OR-
* Healthy adults

Exclusion Criteria:

* Unstable angina, myocardial infarction or revascularization within 3 months
* Symptomatic heart failure
* Creatinine \> 3.0 mg/dl
* Liver enzymes \> 3X upper limit of normal
* Chronic hypoxia
* Significant anemia
* Chronic inflammatory disease
* Pregnancy
* Willing to withdraw statins for duration of study

Primary outcomes:
measure: Vascular reactivity
Secondary outcomes:
measure: Rho kinase expression
measure: Rho kinase activity
measure: eNOS expression
measure: eNOS activity
measure: inflammatory markers
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Mark A Creager, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02334618: Insole Sensor to Determine Optimal Limb Loading in the Rehabilitation of Ankle Fractures
Official title: Clinical Trial of an Insole Sensor to Determine Optimal Limb Loading in the Rehabilitation of Ankle Fractures
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ankle Fracture
Lead sponsor: University of Utah
Sponsor class: OTHER
First posted: 2015-01-08
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who present to the University of Utah emergency department with ankle fractures.

Brief summary: The purpose of this study is to use a novel load monitoring technology to correlate limb loading to ankle fracture outcomes. This study will collect continuous limb loading data and will provide the first objective insight into how limb loading directs fracture healing.


Eligibility criteria: Inclusion Criteria:

* Patient is 18 years of age or older
* Patient has an ankle fracture
* Patient speaks English
* Patient weighs between 100 and 250 pounds
* Patient lives in close enough proximity to the hospital to return for all appointments (\~100 miles)

Exclusion Criteria:

* Patient is younger than 18 years of age
* Patient has multiple fractures that would alter weight bearing protocol
* Patient does not speak English
* Patient weighs less than 100 pounds or more than 250 pounds
* Patient does not live in close enough proximity to the hospital to return for all appointments (\~\>100 miles)
* Patient has a traumatic brain injury that would make it so they cannot consent
* Patient has diabetes

Primary outcomes:
measure: Patient Activity Measure (PAM-13) Questionnaire
timeFrame: Follow Up Visits up to 1-Year
Secondary outcomes:
measure: X-ray (AP and Lateral)
timeFrame: Follow Up Visits up to 1-Year
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: University of Utah Orthopedics Center
state: Utah
Study officials:
affiliation: University of Utah
name: David Rothberg, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05778318: Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19
Official title: Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COVID-19 Pneumonia
Lead sponsor: Qianfoshan Hospital
Sponsor class: OTHER
First posted: 2023-03-21
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: ① For patients infected with the Omicron variant of COVID-19, the diagnostic criteria are confirmed cases of COVID-19 and clinical classification according to the diagnostic criteria of Prevention and Control Protocol for Novel Coronavirus Pneumonia (Trial Eighth Edition) issued by the National Health and Construction Commission; ② The clinical symptoms were classified as mild or ordinary; ③ They have been vaccinated against the COVID-19.

Brief summary: A retrospective analysis was conducted on patients infected with the Omicron variant of COVID-19 diagnosed from August 2022 to now. Patients were divided into observation groups and control groups according to whether or not oral Lianhua Qingwen granules were used. Through data analysis and follow-up, the effectiveness of Lianhua Qingwen in treating patients infected with the Omicron variant of COVID-19 was discussed.


Eligibility criteria: Inclusion Criteria:

* For patients infected with the Omicron variant, the diagnostic criteria are confirmed cases of COVID-19 and clinical classification according to the diagnostic criteria of Prevention and Control Protocol for COVID-19 (Trial Eighth Edition) issued by the National Health and Construction Commission.
* The clinical symptoms were classified as mild or ordinary.
* They have been vaccinated against the COVID-19.

Exclusion Criteria:

* Patients receiving antiviral or antibiotic drugs
* Severe and critical patients with COVID-19.
* Patients with chronic respiratory diseases, bacterial infections of the respiratory system, and other respiratory diseases affecting the study.
* Patients with serious primary diseases of the heart, brain, lung, liver, kidney, and hematopoietic systems, as well as mental diseases.
* Allergic reaction to Lianhua Qingwen granules.
* Excluded patients treated with the same drug as Lianhua Qingwen.

Primary outcomes:
measure: Disappearance rate of symptoms
timeFrame: two weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
state: Shandong
Study officials:
References:
Clinical trial NCT00072618: Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients
Official title: A Phase I/II Multi-Center Study of Weekly Taxotere (Docetaxel) in Combination With Aptosyn (Exisulind) in Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed a Prior Platinum-Containing Regimen
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: NSCLC
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: OSI Pharmaceuticals
First posted: 2003-11-07
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if the combination of Taxotere and exisulind is an effective and safe treatment for patients with advanced NSCLC who have failed a prior platinum-containing regimen.


Eligibility criteria: Inclusion Criteria:

Histologically documented advanced cancer or advanced platinum-refractory non-small cell lung cancer. Platinum refractory defined as progressive disease during a platinum regimen or within 6 months following treatment.

Negative serum pregnancy test, if fertile female. Have not taken sulindac (Clinoril®) on regular basis for any indication for one week prior to enrollment and willing to remain off of sulindac for the duration of the study.

\> 18 years or of legal age. Male patients, or non-pregnant and non-lactating female patients either using adequate birth control (oral contraceptives or Provera), surgically sterile or post-menopausal.

Willingness to remain off chronic NSAIDs (with the exception of ibuprofen, naproxen, or aspirin) for duration of the study. Low dose aspirin for cardiovascular prevention is acceptable.

No treatment with any other chemotherapy or radiotherapy within 2 weeks prior to entering the study.

Exclusion Criteria:

Any condition or any medication which may interfere with the conduct of the study.

Known hypersensitivity to sulindac (Clinoril®) or taxanes. Use of an investigational medication or device within one month of initiating study therapy.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado Health Sciences Center
state: Colorado
city: Chicago
country: United States
facility: University of Chicago Medical Center
state: Illinois
Study officials:
References: